Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.41 |
| ▸ | TNF | P01375 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.37 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.37 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3826333 | 0.98 | CLK1 (0.43) | CLK1DYRK1AMAPK10TNFKDM4E | |
| Hydrochloric Acid SCHEMBL3826318 | 0.96 | CLK1 (0.42) | CLK1DYRK1AMAPK10TNFKDM4E | |
| SCHEMBL276690 | 0.96 | CLK1 (0.44) | CLK1DYRK1AMAPK10TNFKDM4E | |
| Hydrochloric Acid SCHEMBL2978477 | 0.94 | CLK1 (0.43) | CLK1DYRK1AMAPK10TNFKDM4E | |
| SCHEMBL277425 | 0.81 | KDM4E (0.53) | CLK1DYRK1AMAPK10KDM4EMAPKAPK2 | |
| SCHEMBL29569821 | 0.71 | CLK1 (0.54) | CLK1DYRK1AMAPK10TNFKDM4E | |
| SCHEMBL672509 | 0.71 | CLK1 (0.54) | CLK1DYRK1AMAPK10TNFKDM4E | |
| SCHEMBL58112 | 0.71 | PLAU (0.56) | KDM4EPLGPLAU | |
| SCHEMBL25857229 | 0.71 | KDM4E (0.42) | CLK1DYRK1AMAPK10TNFKDM4E | |
| Bromide SCHEMBL9548953 | 0.71 | PTPN22 (0.48) | CLK1DYRK1AMAPK10TNFKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221828-A1 | Process for Preparing 1-Halo-2,7-Naphthyridinyl Derivatives | UCB PHARMA, S.A. (BE) | 2009-09-03 | — | — | US | claimed |
| EP-1999110-A2 | PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES | UCB Pharma, S.A. (BE) | 2008-12-10 | — | — | EP | claimed |
| WO-2007107345-A2 | PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES | UCB PHARMA, S.A. (BE) | 2007-09-27 | — | — | WO | claimed |
| EP-1999110-B1 | PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES | UCB PHARMA SA (BE) | 2009-09-16 | — | — | EP | disclosed |
| US-20090221828-A1 | Process for Preparing 1-Halo-2,7-Naphthyridinyl Derivatives | UCB PHARMA, S.A. (BE) | 2009-09-03 | — | — | US | disclosed |
| EP-1999110-A2 | PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES | UCB Pharma, S.A. (BE) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007107345-A2 | PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES | UCB PHARMA, S.A. (BE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221828-A1 | Process for Preparing 1-Halo-2,7-Naphthyridinyl Derivatives | NPM1, XPO4, BRD7 | CLK1 345/4885DYRK1A 1014/4885MAPK10 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.